Vir Biotechnology (NYSE:VIR) EVP Herbert Virgin Sells 5,560 Shares

Vir Biotechnology (NYSE:VIR) EVP Herbert Virgin sold 5,560 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $42.92, for a total transaction of $238,635.20. Following the sale, the executive vice president now owns 25,560 shares in the company, valued at $1,097,035.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Herbert Virgin also recently made the following trade(s):

  • On Tuesday, September 8th, Herbert Virgin sold 3,805 shares of Vir Biotechnology stock. The stock was sold at an average price of $29.99, for a total value of $114,111.95.
  • On Tuesday, August 11th, Herbert Virgin sold 7,900 shares of Vir Biotechnology stock. The stock was sold at an average price of $51.08, for a total value of $403,532.00.
  • On Tuesday, July 28th, Herbert Virgin sold 7,900 shares of Vir Biotechnology stock. The shares were sold at an average price of $47.99, for a total value of $379,121.00.
  • On Tuesday, July 14th, Herbert Virgin sold 7,900 shares of Vir Biotechnology stock. The stock was sold at an average price of $48.85, for a total value of $385,915.00.
  • On Tuesday, June 23rd, Herbert Virgin sold 5,560 shares of Vir Biotechnology stock. The stock was sold at an average price of $38.99, for a total transaction of $216,784.40.
  • On Friday, June 19th, Herbert Virgin sold 3,510 shares of Vir Biotechnology stock. The stock was sold at an average price of $38.00, for a total transaction of $133,380.00.

NYSE:VIR opened at $28.28 on Friday. The company’s 50-day simple moving average is $45.59 and its 200 day simple moving average is $38.69. Vir Biotechnology has a one year low of $11.65 and a one year high of $75.00.

Vir Biotechnology (NYSE:VIR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.27) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.35. The firm had revenue of $66.99 million during the quarter, compared to the consensus estimate of $2.50 million.

Several large investors have recently bought and sold shares of VIR. Principal Financial Group Inc. purchased a new stake in Vir Biotechnology during the second quarter valued at approximately $1,286,000. Nuveen Asset Management LLC raised its holdings in Vir Biotechnology by 517.6% in the second quarter. Nuveen Asset Management LLC now owns 226,677 shares of the company’s stock worth $9,287,000 after purchasing an additional 189,973 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Vir Biotechnology by 561.7% in the second quarter. Charles Schwab Investment Management Inc. now owns 100,563 shares of the company’s stock worth $4,121,000 after purchasing an additional 85,366 shares in the last quarter. California State Teachers Retirement System raised its holdings in Vir Biotechnology by 527.1% in the second quarter. California State Teachers Retirement System now owns 69,813 shares of the company’s stock worth $2,860,000 after purchasing an additional 58,680 shares in the last quarter. Finally, Perceptive Advisors LLC acquired a new position in shares of Vir Biotechnology during the second quarter valued at about $534,000.

Several research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a report on Wednesday, July 22nd. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Vir Biotechnology in a research report on Monday, August 24th. Goldman Sachs Group raised their price objective on shares of Vir Biotechnology from $43.00 to $48.00 and gave the stock a “neutral” rating in a research report on Monday, August 31st. Needham & Company LLC started coverage on shares of Vir Biotechnology in a research report on Thursday, August 20th. They issued a “buy” rating and a $62.00 price target for the company. Finally, JPMorgan Chase & Co. raised shares of Vir Biotechnology from an “underweight” rating to a “neutral” rating and set a $29.00 price target for the company in a research report on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the stock. Vir Biotechnology presently has a consensus rating of “Hold” and a consensus target price of $47.14.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.

Further Reading: Why is a lock-up period needed for an IPO?

Insider Buying and Selling by Quarter for Vir Biotechnology (NYSE:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.